The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • AFT Pharmaceuticals (AFP) has opened its NZ$2 million (A$1.88 million) share purchase plan
  • This share purchase plan forms part of the company’s capital raising that was announced on June 10, with the company also announcing a NZ$10 million (A$9.42 million) placement
  • Eligible shareholders will be able to purchase up to NZ$50,000 (A$47,000) worth of new shares at NZ$3.75 (A$3.54) each
  • Shares will be allocated on July 2 and then begin trading on the NZX on July 2 and the ASX on July 3
  • AFT will use the money from both the placement and share purchase plan to increase liquidity and reduce debt
  • AFT has ended the day a slight 2.21 per cent in the green with shares trading for $3.70 each

AFT Pharmaceuticals (AFP) has opened its NZ$2 million (A$1.88 million) share purchase plan.

This share purchase plan forms part of the company’s capital raising that was announced on June 10, with the company also announcing a NZ$10 million (A$9.42 million) placement.

A day later the placement was completed with 2.7 million shares issued at a price of NZ$3.75 (A$3.54) each.

This price was a 20.2 per cent discount to the close on June 9 of NZ$4.70 (A$4.43) per share and an 11.1 per cent discount to the 30-day volume-weighted average price of NZ$4.22 (A$3.98).

For the share purchase plan eligible shareholders will be able to purchase up to NZ$50,000 (A$47,000) worth of new shares at the same price as the placement.

The plan is expected to close on June 26 and share will be allocated on July 2. The shares will then begin trading on the NZX on July 2 and the ASX on July 3.

AFT will use the money from both the placement and share purchase plan to increase liquidity and reduce debt.

AFT has ended the day a slight 2.21 per cent in the green with shares trading for $3.70 each in a $363.7 million market cap.

AFP by the numbers
More From The Market Online

OncoSil’s cancer device shows shrink in pancreatic tumours

OncoSil's cancer device shows shrink in pancreatic tumours at a study conducted at the Royal Adelaide…
The Market Online Video

Why Princeton Professor rates BlinkLab’s autism & ADHD screening app

In this interview with Sonia Madigan, Professor Sam Wang of Princeton University discusses the development and…

Orthocell’s Remplir shows 85% success rate in nerve repair study

Orthocell's medical device RemplirTM shows 85% success rate in latest nerve repair study, holding a promise…

ResMed spikes on robust results and global growth spurt

ResMed shares have climbed following the release of the company's strong Third Quarter FY2024 results.